ELTX
NASDAQ · Biotechnology
Elicio Therapeutics Inc
$8.32
+0.71 (+9.33%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| EPS | — | — | — |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| Rev Growth | +12.6% | +22.6% | -0.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 22.74M | 20.95M | 24.25M |
| Total Equity | 120.34M | 113.52M | 121.07M |
| D/E Ratio | 0.19 | 0.18 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |